We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
China, Global, United Kingdom, USA - February 27 2013
Pharmaceutical and biologic manufacturers operate in an increasingly global economy where legal developments in one market may have cascading impacts…
China, European Union, France, Germany, United Kingdom, USA - May 18 2012
Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies.
USA - February 7 2012
On February 2, 2012, the Centers for Medicare and Medicaid Services (“CMS” or “the Agency”) published its much anticipated proposed rule governing the calculation of Average Manufacturer Price (“AMP”), the determination of Best Price, and key pharmacy reimbursement issues (“the Proposed Rule”).
USA - October 21 2011
The Office of the Inspector General of the U.S. Department of Health and Human Services (“OIG”) released its annual Work Plan for Fiscal Year 2012 on October 5, 2011.
USA - October 15 2010
On September 28, 2010, the Office of Inspector General (OIG) of the Department of Health and Human Services issued a Special Advisory Bulletin (the “Bulletin”) regarding OIG’s enforcement initiative to promote manufacturer compliance with reporting requirements for average manufacturer price (AMP) and average sales price (ASP).
